You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 148 No. 8, August 1988 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL INVESTIGATIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (7)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Improved Metabolic Control in Insulin-Dependent Diabetes Mellitus With Insulin and Tolazamide

Udaya M. Kabadi, MD; Marcia R. Birkenholz

Arch Intern Med. 1988;148(8):1745-1749.


Abstract



• The influence of sulfonylurea drugs in enhancing the effect of endogenous insulin is well documented. Furthermore, combination therapy with sulfonylurea and insulin is effective in the treatment of type II diabetes mellitus. Therefore, to assess the efficacy of this type of combination therapy in type I diabetes, we conducted a double-blind clinical trial with tolazamide and insulin in 15 subjects with type I diabetes. The diagnosis of type I diabetes was confirmed by previous episodes of diabetic ketoacidosis and undetectable C-peptide levels in serum samples from blood drawn from patients two hours after breakfast. During the study protocol, placebo or tolazamide was randomly added to insulin and the combination therapy was continued for three months. In the placebo group, levels of fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) did not alter significantly at the end of the study period. However, in the tolazamide group, levels of FPG and HbA1c markedly improved after administration of tolazamide (FPG levels before therapy, 10.8±0.9 mmol/L [mean±SEM]; after therapy, 6.7±0.4 mmol/L; HbA1c levels before therapy, 10.9%±0.6%; after therapy, 9.6%±0.5%). Therefore, adjuvant therapy with tolazamide and insulin may be beneficial in achieving adequate metabolic control in type I diabetes mellitus.

(Arch Intern Med 1988;148:1745-1749)



Author Affiliations



From the Veterans Administration Medical Center, Des Moines; and the Department of Medicine, University of Iowa School of Medicine, Iowa City. Presented in part at the 22nd Annual Meeting of the European Association for the Study of Diabetes, Rome, Sept 17, 1986.


Footnotes



Accepted for publication March 29, 1988.

Reprint requests to Endocrine Section, Medical Service, Veterans Administration Medical Center, Seventh Street and Indian School Road, Phoenix, AZ 85012 (Dr Kabadi).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy of Sulfonylureas with Insulin in Type 2 Diabetes Mellitus
Kabadi and Kabadi
The Annals of Pharmacotherapy 2003;37:1572-1576.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.